Intellia Therapeutics

@intelliatweets

Treating genetic disease at the cutting edge: Intellia is a CRISPR/Cas9 focused biotechnology company. View our guidelines:

Cambridge, MA
intelliatx.com
Geregistreerd in juli 2014
468 foto's en video's Foto's en video's

Tweets

Je hebt @intelliatweets geblokkeerd

Weet je zeker dat je deze Tweets wilt bekijken? @intelliatweets wordt niet gedeblokkeerd door Tweets te bekijken.

  1. Vastgemaakte Tweet
    26 jun.

    News: Today we open a . We’re proud to announce the first clinical data suggesting a single infusion of may potently and precisely inactivate a disease-causing gene, opening the door to treating, reversing or curing previously inaccessible diseases.

    1 antwoord 78 retweets 222 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken
  2. 15 uur geleden

    From July 5 – July 9, Intellia will be closed for our annual summer shutdown. This is just one of the many great employee benefits that we offer! Check out our other benefits here:

    15 vind-ik-leuks
    Ongedaan maken
  3. 4 jul.

    From all of us at Intellia, we wish you a safe, healthy and fun !

    1 retweet 16 vind-ik-leuks
    Ongedaan maken
  4. 2 jul.

    As we wrap up an exciting week, we are thinking again of the thousands of people worldwide living with amyloidosis. We intend to move rapidly to advance NTLA-2001 through the clinic in hopes of halting and even reversing the painful progression of all types of .

    3 retweets 32 vind-ik-leuks
    Ongedaan maken
  5. 1 jul.

    We’re taking a full-spectrum approach to leveraging the power of to develop both in vivo and ex vivo therapies for a broad range of diseases. Learn about our modular platform:

    4 retweets 17 vind-ik-leuks
    Ongedaan maken
  6. 30 jun.

    Why does our latest data matter? It opens the door to address the root cause of many genetic diseases that have not been treatable with other therapeutic approaches.

    1 antwoord 4 retweets 26 vind-ik-leuks
    Ongedaan maken
  7. 30 jun.

    We’re proud to share that we filed a CTA to launch a clinical trial for NTLA-2002, an in vivo candidate targeting the root cause (HAE), a rare, life-threatening disorder. .

    4 antwoorden 13 retweets 86 vind-ik-leuks
    Ongedaan maken
  8. 29 jun.

    This is a big moment for the patients we hope to serve with NTLA-2001 – and for all who can benefit from the promise of genomic medicine. Our CEO, John Leonard, reflects on this milestone:

    2 retweets 20 vind-ik-leuks
    Ongedaan maken
  9. 29 jun.

    We’re doctors. We’re scientists. We’re patients. And we’re only getting started. Today, we thank our world-class team for unlocking the potential of . We’ve made a tremendous start. Now let’s get it done.

    2 retweets 18 vind-ik-leuks
    Ongedaan maken
  10. 28 jun.

    Hear from one of our founders, Rodolphe Barrangou, on this exciting moment in medicine here:

    2 retweets 12 vind-ik-leuks
    Ongedaan maken
  11. 28 jun.

    technology is designed to precisely and permanently inactivate a harmful gene or insert a therapeutic gene to treat disease. Our latest clinical data suggest we have solved the challenge of delivering CRISPR to target cells in the liver with a single dose.

    4 antwoorden 14 retweets 105 vind-ik-leuks
    Ongedaan maken
  12. 28 jun.

    At 8 a.m. this morning, will be hosting an Investor Relations event, where we’ll discuss our recent interim clinical results from our Phase 1 study for . Click here to register for the webcast:

    6 retweets 19 vind-ik-leuks
    Ongedaan maken
  13. 27 jun.

    We are building on Nobel Prize-winning science with the goal to develop medicines that can help patients around the world. We’re in the clinic with our first investigational therapy—and we’re just getting started.

    1 antwoord 6 retweets 34 vind-ik-leuks
    Ongedaan maken
  14. 26 jun.

    The data also bring hope to people living with many other genetic diseases. They suggest a single dose of can precisely edit cells deep in the body to treat the root cause of disease.

    1 antwoord 3 retweets 25 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken
  15. 26 jun.

    We are thrilled to share these encouraging data, which suggest that a single dose may deliver lifelong, life-changing benefits for people with ATTR .

    3 antwoorden 2 retweets 24 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken
  16. 26 jun.

    Our positive interim Phase 1 data support the curative potential of our investigational in vivo therapy for ATTR . Read more about NTLA-2001. here:

    2 antwoorden 29 retweets 79 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken
  17. 26 jun.

    1 antwoord 4 retweets 23 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken
  18. 24 jun.

    Meet Intellia’s new EVP, General Counsel and Corporate Secretary, Jim Basta! Jim will succeed José Rivera, who will now serve as a special advisor. Thank you, José, for being an incredible colleague and building the company to what it is today!

    1 antwoord 6 vind-ik-leuks
    Ongedaan maken
  19. 23 jun.

    Meet Krina, one of our recent new hires. After hearing about Intellia’s work using /Cas9 and company culture through the alumni of her graduate program, she was eager to join. Visit our Careers page to see all of our latest openings:

    7 vind-ik-leuks
    Ongedaan maken
  20. 22 jun.

    More News: Our EVP, Chief Operating Officer, Andrew Schiermeier, Ph.D., will be joining the new company as President and CEO. Thank you, Andrew, for your great leadership and helping Intellia grow to what it is today. Best of luck in your new role!

    1 retweet 12 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
    Ongedaan maken

@intelliatweets heeft nog niet getweet.

Het laden lijkt wat langer te duren.

Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.

    Je bent misschien ook geïnteresseerd in

    ·